CL2022002828A1 - Inhibidores de kras tricíclicos fusionados. - Google Patents

Inhibidores de kras tricíclicos fusionados.

Info

Publication number
CL2022002828A1
CL2022002828A1 CL2022002828A CL2022002828A CL2022002828A1 CL 2022002828 A1 CL2022002828 A1 CL 2022002828A1 CL 2022002828 A CL2022002828 A CL 2022002828A CL 2022002828 A CL2022002828 A CL 2022002828A CL 2022002828 A1 CL2022002828 A1 CL 2022002828A1
Authority
CL
Chile
Prior art keywords
compounds
fused tricyclic
kras inhibitors
kras
inhibitors
Prior art date
Application number
CL2022002828A
Other languages
English (en)
Inventor
Wenyu Zhu
Wenqing Yao
xiaozhao Wang
Chao Qi
Artem Shvartsbart
Rocco Policarpo
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CL2022002828A1 publication Critical patent/CL2022002828A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen compuestos de la fórmula I, métodos de uso de compuestos para inhibir la actividad de KRAS y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de KRAS, como el cáncer.
CL2022002828A 2020-04-16 2022-10-13 Inhibidores de kras tricíclicos fusionados. CL2022002828A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063011089P 2020-04-16 2020-04-16
US202163146899P 2021-02-08 2021-02-08

Publications (1)

Publication Number Publication Date
CL2022002828A1 true CL2022002828A1 (es) 2023-03-31

Family

ID=75870725

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022002828A CL2022002828A1 (es) 2020-04-16 2022-10-13 Inhibidores de kras tricíclicos fusionados.
CL2023002090A CL2023002090A1 (es) 2020-04-16 2023-07-18 Inhibidores de kras tricíclicos fusionados

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023002090A CL2023002090A1 (es) 2020-04-16 2023-07-18 Inhibidores de kras tricíclicos fusionados

Country Status (16)

Country Link
US (1) US20210355121A1 (es)
EP (1) EP4135844A1 (es)
JP (1) JP2023522202A (es)
CN (1) CN115702025A (es)
AU (1) AU2021254794A1 (es)
BR (1) BR112022020841A2 (es)
CA (1) CA3179692A1 (es)
CL (2) CL2022002828A1 (es)
CO (1) CO2022016377A2 (es)
CR (1) CR20220584A (es)
EC (1) ECSP22087539A (es)
IL (1) IL297165A (es)
MX (1) MX2022012780A (es)
PE (1) PE20230825A1 (es)
TW (1) TW202204355A (es)
WO (1) WO2021211864A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
US11453683B1 (en) 2019-08-29 2022-09-27 Mirati Therapeutics, Inc. KRas G12D inhibitors
KR20220091480A (ko) 2019-09-24 2022-06-30 미라티 테라퓨틱스, 인크. 병용 요법
BR112022012106A2 (pt) 2019-12-20 2022-09-20 Mirati Therapeutics Inc Inibidores de sos1
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
AR125782A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
CA3234375A1 (en) * 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en) * 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
AU2022389961A1 (en) 2021-11-22 2024-06-06 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN115317490A (zh) * 2021-12-24 2022-11-11 南通大学附属医院 化合物bml-275在制备改善鼻咽癌预后的药物中的应用
CN114394967B (zh) * 2022-01-28 2023-12-15 宁夏农林科学院农业资源与环境研究所（宁夏土壤与植物营养重点实验室） 一种2-吡唑苯胺与1,3-二羰基化合物合成吡唑并喹啉衍生物的方法
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024015731A1 (en) * 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ATE459616T1 (de) 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
IL153231A0 (en) 2000-06-28 2003-07-06 Smithkline Beecham Plc Wet milling process
IL160915A0 (en) 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
RU2337692C3 (ru) 2001-10-30 2020-11-09 Новартис Аг Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
DK1470124T3 (da) 2002-01-22 2006-04-18 Warner Lambert Co 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
EP1885352A2 (en) 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
WO2009085185A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
DK2342226T3 (en) 2008-09-26 2016-09-26 Dana Farber Cancer Inst Inc HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JO2885B1 (en) 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR101929593B1 (ko) 2010-10-25 2018-12-14 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
CN102655637A (zh) * 2011-03-01 2012-09-05 中兴通讯股份有限公司 一种移动通信系统和组网方法
ES2620521T3 (es) 2011-03-23 2017-06-28 Amgen Inc. Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3
HUE028555T2 (en) * 2011-10-07 2016-12-28 Eisai R&D Man Co Ltd Pyrazolinquinoline Derivatives as PDE9 Inhibitors
AU2016244017B2 (en) * 2015-04-03 2020-07-23 Nant Holdings Ip, Llc Compositions and methods of targeting mutant K-ras
WO2016199943A1 (en) * 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
CA3005089A1 (en) * 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017106634A1 (en) 2015-12-17 2017-06-22 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
DK3394033T3 (da) 2015-12-22 2021-01-04 Incyte Corp Heterocykliske forbindelser som immunmodulatorer
MA44860A (fr) 2016-05-06 2019-03-13 Incyte Holdings Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
ES2930092T3 (es) 2016-07-14 2022-12-07 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
EP3504198B1 (en) 2016-08-29 2023-01-25 Incyte Corporation Heterocyclic compounds as immunomodulators
MY197501A (en) 2016-12-22 2023-06-19 Incyte Corp Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
EP3558985B1 (en) 2016-12-22 2022-09-07 Incyte Corporation Benzooxazole derivatives as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
EP3558989B1 (en) 2016-12-22 2021-04-14 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MX2020011234A (es) * 2018-04-25 2020-11-11 Innate Tumor Immunity Inc Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
EP3790877B1 (en) 2018-05-11 2023-03-01 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
KR20210046023A (ko) * 2018-08-16 2021-04-27 인네이트 튜머 이뮤니티, 인코포레이티드 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제

Also Published As

Publication number Publication date
CN115702025A (zh) 2023-02-14
CL2023002090A1 (es) 2023-12-15
MX2022012780A (es) 2023-01-18
CR20220584A (es) 2023-02-15
PE20230825A1 (es) 2023-05-19
BR112022020841A2 (pt) 2023-05-02
ECSP22087539A (es) 2023-01-31
TW202204355A (zh) 2022-02-01
CA3179692A1 (en) 2021-10-21
CO2022016377A2 (es) 2023-02-27
US20210355121A1 (en) 2021-11-18
EP4135844A1 (en) 2023-02-22
WO2021211864A1 (en) 2021-10-21
JP2023522202A (ja) 2023-05-29
IL297165A (en) 2022-12-01
AU2021254794A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
CO2022016377A2 (es) Inhibidores de kras tricíclicos fusionados
CL2021002995A1 (es) (divisional de solicitud 2922-2020) derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1.
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
GT200800202A (es) Quinazolinas para la inhibicion de pdk1
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
GT201000172A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
CO2022000481A2 (es) Inhibidores de enzimas
UY39477A (es) Compuestos espiro heterocíclicos y métodos de uso
CO2024006030A2 (es) Compuestos de quinolina como inhibidores de kras
CL2022000005A1 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
ECSP21044843A (es) Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
CO2022018636A2 (es) Moduladores de il-17a
CO2022016899A2 (es) Moduladores de il-17a
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
CO2023008475A2 (es) Inhibidores de enzimas
DOP2022000203A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52
AR126389A1 (es) Compuestos tricíclicos como inhibidores de kras
CO2022017969A2 (es) Compuestos de imidazopiridazina con actividad como inhibidores de alk2